This position is responsible for business development efforts related to Caris Pharmatech's oncology clinical trial service offerings which include patient identification, physician outreach, site activation, site management, and all related Just-In-Time clinical trial services.
This position will be responsible for growing and managing a pipeline of potential business partners and clinical trial opportunities from prospecting to contracting within the oncology pharmaceutical, biotech, and CRO sectors.
Work collaboratively with multiple internal departments including clinical research operations, other business development teams, medical affairs, legal, and finance.
This individual will be expected to already have an extensive understanding of oncology clinical research operations, clinical trial services contracting with pharma, clinical trial protocol design, and overall business development process management. Jobs by location. Jobs by company. Jobs by title.
Caris Still on the Hook for Majority Of Whistleblower Allegations
Career Advice. Jobs Locations. Latest News. This is how many companies are likely to have layoffs in the next 3 months. The United Nations said Coronavirus could wipe out this shocking number of jobs by July.
Office Life. These comfortable and professional outfits are work-from-home staples. Interview Tips. Ladders Resume Guide This is the most important resume trick. If you include any of these things on a college resume, it will be thrown in the trash. Cover Letter. Ladders Resume Guide: To include or not include social media links. If you want to achieve your goals 10x faster, you need to stop following routines. Research finds music is the one thing that bring everyone together during a pandemic.
These are the best technologies to use from home during social distancing. If you grew up lower or middle class, you need to develop this upper-class mindset. Brown researchers say this could really help with physician burnout. Tim Ferris says to consider this thought — Especially if your life feels like a mess.
The quarantine might be just what you need to improve your life, career and future. Job Salaries Company Search. Apply Save.
Job Description This position is responsible for business development efforts related to Caris Pharmatech's oncology clinical trial service offerings which include patient identification, physician outreach, site activation, site management, and all related Just-In-Time clinical trial services. With potential pharma and CRO partners, this individual will be. About Caris Life Sciences. Total Jobs:. Total Experts:. Average Pay:. Total value of jobs:.
More Jobs at Caris Life Sciences.Caris paved the way for precision healthcare in order to help patients and their physicians find the right treatment for cancer and other complex diseases based on an understanding that each patient is unique and deserves treatment options designed specifically for them.
By combining state-of-the-art testing methodologies with emerging technologies and evolving medical and scientific insight, Caris is able to focus on individual outcomes AND advance the way healthcare is delivered around the world. Our scientific and medical professionals can choose to work from our Phoenix, AZ office in one of two capacities:. Our corporate professionals and field based sales team work cross- functionally to drive business success.
Because we are committed to advancing scientific discovery, the pace of our business model must responsively adjust to meet the capabilities and needs of the marketplaces we serve. This increases the shared alignment, magnitude, visibility, and empowerment of each and every role forming a results-oriented environment. With those expectations and empowerment comes the opportunity for great rewards for employees who go above and beyond to achieve business results.
If you are ready for the challenges and opportunities that come with an environment defined by high expectations and empowerment to achieve, Caris may be the place for you to redefine your career. Type and press 'enter' to search Search.
My Story. Share This Page. Learn more about achieving success at Caris and our various benefits. View Benefits. Operational laboratory delivering superior insights to physicians and directly impacting the treatment of cancer patients today. Our sales team members operate in the field servicing our nationwide client base.Welcome to the top European Pharmaceutical News Portal.
Stay updated on the latest Pharma News. Subscribe now, it's free! The new positions reflect the Company's rapid scaling for an aggressive growth strategy in the region. Ian Abercrombie joins Caris from Genzyme Therapeutics, where he most recently served as the European Director of Oncology, with leadership responsibility for commercial activities and performance for the company's key hematology product in EU, Eurasian and Australian affiliates.
Ian Walker joins the company from his most recent position as Global Program Director of Molecular Diagnostics for Novartis, where he helped to set up the business unit and led the strategy, implementation and execution of the company's first molecular diagnostics program.
Moorhead, President European Operations. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists.
Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome TM platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases.
The company is headquartered in the Dallas metroplex, operates laboratories in the Dallas, Phoenix and Boston metro areas and is entering the European markets through its first international location, in Switzerland. For more information, visit www.In an Oct. Solis denied the majority of the motion for dismissal by defendant Caris, granting only the argument that the relators failed to plead specific facts demonstrating that payment of travel fees and honoraria to physicians attending Caris-sponsored meetings actually induced any Medicare claims to be submitted.
Caris Life Sciences Inc. Caris filed a motion to dismiss a whistleblower lawsuit brought by former employees of Caris based on the argument that the plaintiffs failed to state a specific claim for which relief can be granted as defined in the Federal Rule of Civil Procedure 9 b. The lawsuit was brought by Marsha Fontanive, a former sales representative, and Lindsey Vitez, who had worked in the billing department.
There have been several recent cases that have used this rule as an argument to get false claims lawsuits dismissed, if not entirely, at least partially. The ruling allows the False Claims Act FCA case to go forward, exposing Caris to a variety of allegations and potentially significant fines and punishments if it loses in the end.
The case is important to those laboratories and life science companies that perform similar testing and use similar marketing strategies and techniques, such as those used by pharmaceutical companies, to increase referrals for their products.
It is also important to laboratories performing and billing for laboratory-developed and genetic tests that are considered somewhat controversial by some experts concerning their efficacy and use in diagnosing or treating patients. One of the dangers of a case like this is the exposure to public scrutiny concerning the way these laboratories bill for and market their tests and how well established and documented is the claimed clinical use for these tests.
Other whistleblowers that follow the case may note similar activities by their employers and may believe they can make a similar case against their employing lab. Regarding the billing allegations, the relators claim that Caris billed for technical component services that did not qualify, services that were not reasonable and necessary, unbundling, double billing, overbilling certain pathology and cytogenetics services, and billing for undocumented services.
The specific requirements of this kind of billing are often unique and involve rules that can be different than the rules applicable to many common laboratory tests. This can lead employees to believe that something improper is going on when, in fact, there is nothing untoward going on at all. However, in this case, according to the complaint filed, the relators apparently have provided a fairly substantial amount of records and documentation to lead Solis to allow the case to proceed.
One particular allegation was that Caris billed for hematology tests that were compromised because the samples were exposed to excessive heat during transport to the laboratory. According to the complaint, Caris knew the samples were compromised but performed and reported the tests anyway and then billed Medicare for them. In another allegation, the relators assert that Caris filed false claims because it billed for Target Now tests on first-line surgical specimens even though it had no documentation or evidence to support the efficacy or benefit to patients.
Other allegations include that Caris employees changed the date of service on some claims and added diagnosis codes taken from Medicare coverage policies to avoid denials. The first is the waiver of technical component TC bills to hospitals that did not qualify for any exception under Medicare billing rules that would permit Caris to bill directly to Medicare.
In this case, Caris was supposed to bill the hospital for the TC. However, in meetings with sales representatives, Caris purportedly feared that hospitals who were billed for the TCs would stop referring Target Now tests to Caris.
Caris allegedly held these bills while it tried to qualify the hospitals, unsuccessfully, so it could file the claims directly to Medicare. Meanwhile, Caris continued to bill for the professional components of these tests.
The second AKS allegation concerned alleged illegal kickbacks to physicians who attended Caris meetings disguised as travel expenses and honoraria.James Xue is a veteran entrepreneur with extensive experience spans from US to China and from small biotech to multi-national biopharmaceutical companies.
Over the last two decades, Dr. Xue led or was involved in several start-up companies and situations as well as managed sizable business and operations that contributed to his unique insight and deep knowledge in the biotech industry.
Prior to CANbridge, he was a senior executive at Genzyme where he spent 10 years in various managerial positions with increasing responsibilities. Xue holds a B. Glenn brings more than 15 years of experience in the healthcare sector globally, as an investor, investment banker, and strategy consultant.
Prior to this, Glenn spent more than a decade investing in the healthcare sector globally. Prior to founding his consulting practice, Dr. Before then, Dr.
He holds multiple patents and awards and has authored scores of peer-reviewed publications, presentations and book chapters. Most recently, he was Vice President, Emerging Markets at Bioverativ, a Sanofi company, in Boston, MA, where he established regional structures for emerging markets and oversaw country launches in multiple emerging markets, including Australia, Columbia and Taiwan.
Before then, Mr. Cheresky was Executive Director, Routes -to-Care Strategy, Ultragenyx Pharmaceuticals, in Novato, CA, where he developed a strategy for improving patient treatment access and provided direction to the medical field team. Earlier, Mr. Annie Teng has a strong background in oncology and rare disease.
Zhang brings to the position considerable regulatory experience in China in oncology and rare diseases. Additionally, Ms.
Zhang provided regulatory support for the maintenance and growth of 15 oncology products, and grew the team from 5 to 14 people. She was also a key contributor to the Novartis oncology pipeline development and regulatory strategy in China. From toMs. In andMs. Zhang was a speaker at China Rare Disease Summit.
Prior to Novartis, Ms. Zhang was Associate Director of Regulatory Affairs at Genzyme China, where she is the head of the regulatory affairs and focused on rare diseases. Before then, she worked in regulatory affairs at several companies, including Shanghai Roche and Sanofi China. She is also a licensed pharmacist. Lisa Li is a seasoned leader in the pharmaceutical industry in China with comprehensive knowledge and rich experience in sales and marketing.
Most recently, she was Commercial Director for Rheumatology, Japan-Asia Pacific Region at AbbVie, where she was responsible for driving the regional strategy of the Rheumatology franchise for Humira and ensuring Upadacitinib launch readiness in top markets such as Japan, Australia, Taiwan, Korea and China.
Prior to this, she was the Business Unit Director for Immunology in China where she was instrumental in improving the strategies, planning and processes to build an effective business unit and drive business growth. Lisa obtained her bachelor degree of medicine from Shanghai Jiao Tong University.
Jeff brings with him 23 years of extensive experience in pharmaceutical finance management and operations. His responsibilities covered 6 BUs with combined revenues of 2 billion euros and a team with 20 staffs.
She led the delivery of all components of a clinical study to time, cost, and quality from Study Specifications SS through study closeout activities and Clinical Study Report CSR for regional trials, China registration trials and Phase I trials. Chris has over 17 years of bio-pharmaceutical experience in HR management in an all-round way, including 11 years of professional experience in Human Resource Management of a US listed company.Under the terms of the agreement, Caris is eligible to receive several million dollars in clinical development milestones and undisclosed downstream royalty payments.
Evofosfamide previously known as TH is an investigational hypoxia-activated prodrug of a DNA cross-linking agent that is preferentially activated under hypoxic tumor conditions, a feature of many solid tumors. However, data from the MAESTRO study demonstrated meaningful improvement in overall survival in a subgroup of patients from Japan, in which the risk of death was reduced by 48 percent for patients receiving evofosfamide compared to patients in the control arm.
Currently being utilized in discovery research, advanced diagnostics and drug development programs across multiple diseases, the ADAPT Biotargeting System also has potential utility in drug delivery, disease monitoring and direct therapeutic applications.
Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state s. With more thanclinical cases, CMI provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. To learn more, please visit www. This approach offers broad potential to treat a variety of cancers.
By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.
Threshold Media Inquiries: Denise Powell denise redhousecomms. Toggle navigation. My Story.Each patient requires a more intelligent and comprehensively designed treatment strategy to enable them to fight their disease most effectively.
The current time it takes for us to deliver molecular insights to personalize medicine most frequent turnaround time. Turnaround time for Caris profiling is days.
Caris Molecular Intelligence MI Profile reports are built to maximize clinical utility in an easy-to-interpret format. We understand that clinicians need treatment information fast. Caris Molecular Intelligence enables the delivery of precision medicine by providing oncologists with clinically actionable and individualized cancer treatment information to help personalize cancer care.
Caris Molecular Intelligence provides therapeutic insights designed to aid oncologists in personalizing cancer therapies for their patients.
Based on the clinical literature, biomarker and therapeutic associations are best analyzed by specific technologies looking for explicit genomic and proteomic aberrations. Learn more about our profiling technologies. View a sample report.
After the specimen and required paperwork have been received by Caris Life Sciences, the ordering physician will receive the report in approximately days. Caris Molecular Intelligence is performed in our state-of-the-art, 66, sq-ft laboratory in Phoenix, Arizona. Yes, Caris Molecular Intelligence is typically reimbursed by Medicare and other insurance providers. Depending on the profile ordered, the number of markers analyzed and technologies used, the cost will differ among the various tumor profiling options.
Learn more. Toggle navigation. My Story. Comprehensive Tumor Profiling A better foundation for molecular intelligence with comprehensive tumor profiling. For Physicians. For Biopharma. Page Scroll Button.